Compare Macy's Inc (M) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Sana Biotechnology Inc — how do they compare? Macy's Inc trades at $22.7 (market cap $5.95B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Macy's Inc is far larger — about 7.1× Sana Biotechnology Inc's market cap, and Macy's Inc pays a 3.36% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Sana Biotechnology Inc for 23 Days on average.
| M | SANA | |
|---|---|---|
Market Cap | $5.95B | $836.71M |
Volume | 6,030,644 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $5.92 |
52-Week Low | $16.51 | $2.68 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | $9.75B | $749.96M |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.67, down 0.53% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27, supported by a 15.99% ROE. Recent earnings have consistently beaten estimates, and the company's 'A Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has declined from 2022 peaks. Cash flow trends are improving, with net cash flow turning positive in 2024 and 2025.
The outlook is cautiously optimistic, with a consensus price target of $24.25 offering potential upside. Investment opportunities include deep value, dividend yield, and successful turnaround execution. Key risks are competitive pressures, uneven sales growth, and macroeconomic sensitivity affecting consumer spending. Analyst sentiment is mixed, with 32% buy ratings but 51% hold, reflecting uncertainty around sustained momentum.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
